ZENSUN ENTERPRISES LIMITED
(
(
Key Takeaways from the Heart Failure Pipeline Report*Over 75+ companies and 90+ pipeline drugs in Heart Failure are in various stages of development, and their anticipated acceptance in the Heart Failure market would significantly increase market revenue. *Leading Heart Failure companies developing novel drug candidates to improve the Heart Failure treatment landscape include
Heart Failure Overview
Heart failure (HF) is a syndrome caused by structural and functional defects in the myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis, and genetic mutations. Heart failure is a pathological condition in which the heart is unable to pump enough blood to the rest of the body because it is either unable to fill with a sufficient volume of blood or unable to generate sufficient force to pump out enough blood. Dysfunction of the pericardium, myocardium, endocardium, heart valves, or great vessels alone or in combination is also associated with Heart Failure.
Heart Failure Pipeline Analysis: Drug Profile
Tirzepatide:
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that integrates the actions of both incretins into a single novel molecule. Glucagon-like peptide 1 receptor is a hormone that may complement the effects of Glucagon-like peptide-1 receptor agonist. In preclinical models.
Finerenone (BAY94-8862): Bayer
Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block the harmful effects of the overactivated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. Current steroidal MRAs on the market have proven to be effective in reducing cardiovascular mortality in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, they are often underutilized due to the incidence of hyperkalemia, renal dysfunction, and anti-androgenic / progestogenic side effects.
The initiation of the Phase III FINEARTS-HF study (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in patients with Heart Failure) builds upon the robust Phase II studies ARTS-HF and ARTS-DN which investigated the efficacy and safety of finerenone in patients with heart failure and chronic kidney disease, respectively. Data from the Phase II study program ARTS were presented at
Cardi AMP Cell Therapy:BioCardia
CardiAMP Cell Therapy uses a patient's own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body's natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and more successful for enhancing cell retention.
Firibastat:Quantum Genomics
Firibastat is the first drug candidate in a new class of therapeutic agents called BAPAIs (Brain Aminopeptidase an Inhibitors). Firibastat is a prodrug that releases EC33, a specific and selective inhibitor of Aminopeptidase A in the brain, thereby preventing the production of angiotensin III in the brain. After collecting excellent data on animal efficacy and human safety in the Phase IIa study,
HU 6:
HU6 is a controlled metabolic accelerator (CMA) that provides a novel, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat throughout the body.
Discover more about the emerging Heart Failure drugs @ Heart Failure Treatment Drugs
Heart Failure Pipeline Therapies and Key Companies*Tirzepatide:
And many others
Heart Failure Pipeline Therapeutics Assessment
Phases
DelveInsight's Report covers around 5+ products under different phases of clinical development like*Late-stage products (Phase III) *Mid-stage products (Phase II) *Early-stage product (Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates
Route of Administration
Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as*Intra-articular *Intraocular *Intrathecal *Intravenous *Ophthalmic *Oral *Parenteral *Subcutaneous *Topical *Transdermal
Molecule Type
Products have been categorized under various Molecule types such as*Oligonucleotide *Peptide *Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Heart Failure Pipeline Report*Coverage: Global *Key Heart Failure Companies:
Find out more about the Heart Failure treatment options in development @ Heart Failure Clinical Trials
Table of Contents
1. Heart Failure Introduction
2. Heart Failure Executive Summary
3. Heart Failure Overview
4. Heart Failure Pipeline Therapeutics
5. Heart Failure Late-Stage Products (Phase III)
6. Heart FailureMid-Stage Products (Phase II)
7. Heart Failure Early Stage Products (Phase I/II)
8. Heart Failure Preclinical Stage Products
9. Heart Failure Discovery Stage Products
10. Heart Failure Therapeutic Assessment
11. Heart Failure Inactive Products
12.
13. Heart Failure Unmet Needs
14. Heart Failure Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company
Contact Person:
Email: info@delveinsight.com
Phone: 919650213330
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/consulting/due-diligence-services
Source: www.abnewswire.com
.
(C) 2023 M2 COMMUNICATIONS, source
